HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance
November 6, 2023 4:05 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.75, $0.05 better than the analyst estimate of $0.70. Revenue for the quarter came in at $216 million versus the consensus estimate of $218.7 million.
GUIDANCE:
Halozyme Therapeutics sees FY2023 EPS of $2.70-$2.80, versus the consensus of $2.65.... More
